Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study.
Holte H, Leppä S, Björkholm M, Fluge O, Jyrkkiö S, Delabie J, Sundström C, Karjalainen-Lindsberg ML, Erlanson M, Kolstad A, Fosså A, Ostenstad B, Löfvenberg E, Nordström M, Janes R, Pedersen LM, Anderson H, Jerkeman M, Eriksson M. Holte H, et al. Among authors: lofvenberg e. Ann Oncol. 2013 May;24(5):1385-92. doi: 10.1093/annonc/mds621. Epub 2012 Dec 17. Ann Oncol. 2013. PMID: 23247661 Free article. Clinical Trial.
Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group.
Axdorph U, Stenke L, Grimfors G, Carneskog J, Hansen J, Linder O, Ljungman P, Löfvenberg E, Malm C, Simonsson B, Turesson I, Vilén L, Udén AM, Björkholm M; Swedish CML Group. Axdorph U, et al. Among authors: lofvenberg e. Br J Haematol. 2002 Sep;118(4):1048-54. doi: 10.1046/j.1365-2141.2002.03765.x. Br J Haematol. 2002. PMID: 12199784 Free article. Clinical Trial.
High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia.
Hallböök H, Simonsson B, Ahlgren T, Björkholm M, Carneskog J, Grimfors G, Hast R, Karlsson K, Kimby E, Lerner R, Linder O, Linderholm M, Löfvenberg E, Malm C, Nilsson PG, Paul C, Stenke L, Stockelberg D, Tidefelt U, Turesson I, Uden-Blome AM, Vilen L, Wahlin A, Winquist I, Smedmyr B. Hallböök H, et al. Among authors: lofvenberg e. Br J Haematol. 2002 Sep;118(3):748-54. doi: 10.1046/j.1365-2141.2002.03685.x. Br J Haematol. 2002. PMID: 12181041 Free article. Clinical Trial.
Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support.
Gulbrandsen N, Wisløff F, Brinch L, Carlson K, Dahl IM, Gimsing P, Hippe E, Hjorth M, Knudsen LM, Lamvik J, Lenhoff S, Løfvenberg E, Nesthus I, Nielsen JL, Turesson I, Westin J; Nordic Myeloma Study Group. Gulbrandsen N, et al. Among authors: lofvenberg e. Med Oncol. 2001;18(1):65-77. doi: 10.1385/MO:18:1:65. Med Oncol. 2001. PMID: 11778972 Clinical Trial.
Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma.
Walsh SH, Thorsélius M, Johnson A, Söderberg O, Jerkeman M, Björck E, Eriksson I, Thunberg U, Landgren O, Ehinger M, Löfvenberg E, Wallman K, Enblad G, Sander B, Porwit-MacDonald A, Dictor M, Olofsson T, Sundström C, Roos G, Rosenquist R. Walsh SH, et al. Among authors: lofvenberg e. Blood. 2003 May 15;101(10):4047-54. doi: 10.1182/blood-2002-11-3479. Epub 2003 Mar 13. Blood. 2003. PMID: 12637326 Free article.
No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease.
Hast R, Hellström-Lindberg E, Ohm L, Björkholm M, Celsing F, Dahl IM, Dybedal I, Gahrton G, Lindberg G, Lerner R, Linder O, Löfvenberg E, Nilsson-Ehle H, Paul C, Samuelsson J, Tangen JM, Tidefelt U, Turesson I, Wahlin A, Wallvik J, Winquist I, Oberg G, Bernell P. Hast R, et al. Among authors: lofvenberg e. Leukemia. 2003 Sep;17(9):1827-33. doi: 10.1038/sj.leu.2403035. Leukemia. 2003. PMID: 12970783 Clinical Trial.
Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group.
Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, Wislöff F, Brinch L, Carlson K, Carlsson M, Dahl IM, Gimsing P, Hippe E, Johnsen HE, Lamvik J, Löfvenberg E, Nesthus I, Rödjer S. Lenhoff S, et al. Among authors: lofvenberg e. Blood. 2000 Jan 1;95(1):7-11. Blood. 2000. PMID: 10607678 Free article. Clinical Trial.
37 results